OMNITROPE
Drug
Sandoz Inc.
Total Payments
$186,707
Transactions
785
Doctors
167
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $43.34 | 2 | 2 |
| 2023 | $163.49 | 6 | 6 |
| 2022 | $525.03 | 29 | 17 |
| 2021 | $391.20 | 23 | 18 |
| 2020 | $16,447 | 30 | 20 |
| 2019 | $47,432 | 127 | 60 |
| 2018 | $57,679 | 226 | 90 |
| 2017 | $64,026 | 342 | 113 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $119,153 | 33 | 63.8% |
| Consulting Fee | $30,458 | 7 | 16.3% |
| Food and Beverage | $13,006 | 696 | 7.0% |
| Grant | $10,000 | 1 | 5.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,184 | 24 | 4.9% |
| Travel and Lodging | $4,905 | 24 | 2.6% |
Payments by Type
Research
$119,153
33 transactions
General
$67,554
752 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| POST-APPROVAL SAFETY STUDY TO MONITOR THE LONG-TERM SAFETY AND EFFICACY OF OMNITROPE? IN INFANTS, CHILDREN AND ADOLESCENTS (?PATRO CHILDREN? OR THE ?STUDY?) | Sandoz Inc. | $42,253 | 1 |
| POST-APPROVAL SAFETY STUDY TO MONITOR THE LONG-TERM SAFETY AND EFFICACY OF OMNITROPE IN INFANTS CHILDREN AND ADOLESCENTS PATRO CHILDREN OR THE STUDY | Sandoz Inc. | $39,500 | 1 |
| Post-Approval Safety Study to monitor the long-term safety and efficacy of Omnitrope in infants, children and adolescents | Sandoz Inc. | $22,600 | 0 |
| Post Approval Safety Study to monitor the long term safety and efficacy of Omnitrope in infants children and adolescents PATRO Children or the Study | Sandoz Inc. | $8,800 | 1 |
| POST-APPROVAL SAFETY STUDY TO MONITOR THE LONG-TERM SAFETY AND EFFICACY OF OMNITROPE IN INFANTS, CHILDREN AND ADOLESCENTS PATRO CHILDREN OR THE STUDY | Sandoz Inc. | $6,000 | 1 |
Top Doctors Receiving Payments for OMNITROPE — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Overland Park, KS | $58.64 | 4 |
| , MD, FACE | Endocrinology, Diabetes & Metabolism | Columbus, OH | $57.76 | 3 |
| , MD | Pediatric Endocrinology | Sleepy Hollow, NY | $54.88 | 3 |
| , M.D | Pediatric Endocrinology | Jackson, MS | $54.42 | 3 |
| , M.D | Pediatrics | Jackson, MS | $51.90 | 3 |
| , MD | Endocrinology, Diabetes & Metabolism | Tulsa, OK | $51.81 | 4 |
| , M.D | Pediatrics | Mobile, AL | $51.31 | 3 |
| , MD | Pediatric Endocrinology | Mobile, AL | $51.31 | 3 |
| , MD | Pediatrics | Mobile, AL | $50.41 | 3 |
| , M.D | Pediatrics | Topeka, KS | $50.33 | 4 |
| , MD | Pediatric Endocrinology | Charlotte, NC | $46.99 | 2 |
| , MD | Pediatrics | Charlotte, NC | $46.99 | 2 |
| , MD | Pediatric Endocrinology | Miami, FL | $45.11 | 2 |
| , M.D | Pediatric Endocrinology | Miami, FL | $45.11 | 2 |
| , MD | Pediatric Endocrinology | Miami, FL | $45.11 | 2 |
| , M.D | Pediatrics | Santa Monica, CA | $45.06 | 2 |
| , MD | Pediatrics | Orange, CA | $44.33 | 2 |
| , M.D | Internal Medicine | Wichita, KS | $43.24 | 3 |
| , MD | Pediatric Endocrinology | Jamaica, NY | $42.21 | 3 |
| , M.D | Pediatric Endocrinology | Palm Beach Gardens, FL | $41.27 | 2 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Hackensack, NJ | $41.21 | 3 |
| , M.D | Pediatric Endocrinology | Fresno, CA | $40.06 | 2 |
| , M.D | Internal Medicine | Florissant, MO | $39.86 | 3 |
| , M.D | Pediatrics | Salina, KS | $39.74 | 3 |
| , M.D | Pediatric Endocrinology | Long Beach, CA | $38.36 | 2 |
Ad
Manufacturing Companies
- Sandoz Inc. $186,707
Product Information
- Type Drug
- Total Payments $186,707
- Total Doctors 167
- Transactions 785
About OMNITROPE
OMNITROPE is a drug associated with $186,707 in payments to 167 healthcare providers, recorded across 785 transactions in the CMS Open Payments database. The primary manufacturer is Sandoz Inc..
Payment data is available from 2017 to 2024. In 2024, $43.34 was paid across 2 transactions to 2 doctors.
The most common payment nature for OMNITROPE is "Unspecified" ($119,153, 63.8% of total).
OMNITROPE is associated with 5 research studies, including "POST-APPROVAL SAFETY STUDY TO MONITOR THE LONG-TERM SAFETY AND EFFICACY OF OMNITROPE? IN INFANTS, CHILDREN AND ADOLESCENTS (?PATRO CHILDREN? OR THE ?STUDY?)" ($42,253).